1235480-93-9

Basic information

• Product Name: methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate
• Synonyms: methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate
• CAS NO: 1235480-93-9
• Molecular Weight: 251.282
• Mol File: 1235480-93-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate(1235480-93-9)
• EPA Substance Registry System: methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate(1235480-93-9)

Safety Data

• Hazardous Substances Data: 1235480-93-9(Hazardous Substances Data)

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 56026-36-9 methyl 6-(hydroxymethyl)nicotinate 

Relevant articles and documents

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.